Epizyme (EPZM) specializes in an epigenetic therapy approach to human diseases, including cancers. This is a new field and potentially a revolutionary one. Proving a drug from the epigenetics platform can work well enough to get FDA approval would be a big advance for medicine and biotechnology.
Epizyme appears to be near that goal. Epizyme submitted an NDA (new drug application) to the FDA for Tazemetostat as a therapy for patients with metastatic or locally advanced epithelioid sarcoma (who are not eligible for curative surgery) on May 30. This is an accelerated approval